Results 61 to 70 of about 150,527 (224)
Real‐World Use of Rezafungin for the Treatment of Challenging Aspergillus Infections
Mycoses, Volume 69, Issue 11, November 2026.ABSTRACT Background Aspergillus infections can pose significant treatment challenges, due in part to increasing triazole resistance. Clinical insight is needed to understand the potential for rezafungin, a next‐generation echinocandin with once‐weekly dosing, to address some limitations of current treatments for Aspergillus infections.
Neil Stone +9 more
wiley +1 more source
Monaldi Archives for Chest Disease, 2016 Non-tuberculous mycobacterias (NTMs) have many clinical manifestations in humans, depending on the underlying immunological status. We present a patient with Mycobacterium avium intracellulare pulmonary infection and co-existing, biopsy proven non ...
R.M. Jones +3 more
doaj +1 more source
ChemMedChem, Volume 21, Issue 20, 28 October 2026.Nontuberculous mycobacteria (NTM) mainly Mycobacterium avium complex (MAC), are emerging pathogens responsible for pulmonary infections. The efficacy of the standard treatment is therefore compromised by the emergence of intrinsic and acquired resistance in MAC.
Elise Si Ahmed Charrier +6 more
wiley +1 more source
IMMUNOPATOLOGIYa, OBUSLOVLENNAYa ATIPIChNYMI MIKOBAKTERIYaMI MYCOBACTERIUM AVIUM
, 2014 Иммунопатология, обусловленная атипичными микобактериями Mycobacterium avium.
M. M. Averbakh
core +1 more source
Journal of Family Medicine and Primary Care, 2019 A 40-year-old man presented with refractory pulmonary Mycobacterium avium complex infection, despite administration of antituberculous drugs for 2 years.
Tatsuya Nogami
doaj +1 more source
MicrobiologyOpen, Volume 15, Issue 5, October 2026.A novel nanoformulation consisting of ampicillin (Amp), l‐glutamic acid (l‐glu), and iron oxide nanoparticles was prepared. l‐glu–Fe3O4–Amp NPs exhibited a controlled drug release profile over a certain period of time. The antibacterial effectiveness of the formulation was proven by agar well diffusion and the LIVE/DEAD BacLight fluorescent assays. The
Mehmet Demirel +6 more
wiley +1 more source
Post‐Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management
MedComm, Volume 7, Issue 10, October 2026.A comprehensive review on post‐tuberculosis lung disease (PTLD) addresses the epidemiology, pathogenesis, clinical phenotypes and management, risk factors, prevention and systems approach, and future directions. This review provides standardized definitions, mechanistic insights and biomarkers of PTLD development, and clinical strategies for PTLD ...
Radha Gopalaswamy, Selvakumar Subbian
wiley +1 more source
Lesión cútanea por mycobacterium avium intracelular [PDF]
, 2019 Mycobacterium avium intracellulare (MAC) is one of the mycobacterias most frequently found in patients with HIV infection, but their frequency is decreasing and has been associated to active antiretroviral therapy (HAART) and prophylactic ...
Gaviria, Mónica Alejandra +2 more
core
MedComm, Volume 7, Issue 10, October 2026.Alveolar macrophages: development, respiratory homeostasis, signal pathways, diseases, and therapeutic opportunities: During embryonic development, fetal progenitors migrate to the developing lungs via a CX3CR1‐dependent mechanism to establish the TrAM pool.
Sihan Yang +4 more
wiley +1 more source
International Journal of Infectious Diseases, 2019 Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal ...
Sylvain Lescuyer +9 more
doaj +1 more source